Links

Natural killer cells kill human melanoma cells with characteristics of cancer stem cells.

Natural killer activity of peripheral-blood mononuclear cells in breast cancer patients

Use of natural killer cells as immunotherapy for leukaemia.

Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck

Natural killer cell-directed therapies: moving from unexpected results to successful strategies.

Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies

Maintenance immunotherapy in metastatic breast cancer.

Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components.

Autologous Immune Enhancement therapy for Advanced Carcinoma of Pancreas-A Case

Report Potential role of natural killer cells in controlling growth and infiltration of AIDS-associated primary effusion lymphoma cells.

Antitumor activity of cytokine-induced killer cells against human lung cancer.

A Report of Three Patients Treated with Immunocell Therapy with Imatinib Mesylate

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.

Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy

Chemoimmunotherapy in the treatment of metastatic gastric cancer.

Autologous Immune Enhancement Therapy (AIET) for a Case of Acute Myeloid Leukemia (AML) - Our Experience

Efficacy of Immuno-cell Therapy in Patients with Advanced Pancreatic Cancer

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.

Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma.

Autologous natural killer cell therapy for human recurrent malignant glioma

Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Induction of potent antitumour natural-killer cells from peripheral blood of patients with advanced prostate cancer

Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial.

Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo

Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial.

A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma.

Immuno-cell therapy of cancer in Japan

Clinical Benefit of Non-Toxic therapy in Patients with Advanced Cancer (Opinion)

Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.

Cancer regression induced by modified CTL therapy is regulated by HLA class II and class I antigens in Japanese patients with advanced cancer.

Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.